针对血液癌症的双特异单克隆抗体的最新情况
1City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Current opinion in oncology
|August 8, 2023
概括
新的双特异性抗体显示出治疗多发性骨髓瘤和某些淋巴瘤的前景. 这些先进疗法为复发性或耐药性血液瘤患者提供了有效的选择.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 双特异性抗体正在成为血液性恶性瘤中重要的治疗类.
- 最近的批准针对关键的B细胞恶性瘤,包括多发性骨髓瘤,卵泡性淋巴瘤和扩散性大B细胞淋巴瘤.
结论:
- 双特异性抗体正在改变多发性骨髓瘤和B细胞淋巴瘤的治疗模式.
- 尽管有可控的毒性,但这些药物代表了治疗耐火性血液癌症的关键进步.
相关概念视频
01:31Hybridoma Technology
14.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.9K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K